ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PCSA / forecast
SCNX (28) ADXN (48) LGVN (27) GELS (54) ⌘ Pro Terminal →

Processa Pharmaceuticals Inc. (PCSA) 12-Month Stock Forecast & Price Target Cone

$1.85 -2.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.84

Processa Pharmaceuticals Inc. (PCSA) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $5.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PCSA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PCSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.85 (-2.12% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PCSA ranks #493 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PCSA compare to SCNX and ADXN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PCSA carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SCNX (Scienture Holdings Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and ADXN (Addex Therapeutics Ltd) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $5.3M). Among the 5-stock peer group, PCSA leads on earnings multiple (N/A) while PCSA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PCSA?
▼

Per PCSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533743), Processa Pharmaceuticals Inc. generated $39.2M in revenue (+16.1% YoY), -$13.6M in net income, and -$11.4M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.84 (-0.57%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510039
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (7)Whales (8)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-8.6% Base Target
$11 Bull$2 Base$1 Bear
📬 FREE PCSA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PCSA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY PCSA SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (23% of score)

FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 55.7 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
31
Grade E$1.77+1.1% Next Q
Q2 (-2Q)
34
Grade E$1.79+1.7% Next Q
Q3 (-1Q)
36
Grade E$1.82+1.6% Next Q
Current
39
Grade D-$1.85-7.6% Hist 90D α
Trajectory: E (31) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PCSA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PCSA currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.84) and Max Pain ($1.94) forces dealer call-delta covering toward $10.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PCSA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PCSA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 39%NO 61%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your PCSA Position Size: $10,000

Shares at $1.85: 5405.4 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $1.32
$7,135
$-2,865 (-28.6%)
12M Consensus BaseTarget $1.69
$9,135
$-865 (-8.6%)
12M Bull Case BreakoutTarget $10.76
$58,162
+$48,162 (+481.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$274%A
Goldman SachsSector Coverage LeadUNDERPERFORM$1069%B
JP MorganUS Large-Cap ResearchSELL$258%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PCSA)

  • ✓Walkthrough of PCSA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PCSA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.97%▼ DESCENDING CHANNEL
2026-11-03O $1.89H $1.89L $1.85C $1.85VOL 25.4K
RES: $2.06SUP: $0.79SMA50: $1.84SMA200: $2.34
$5.03$3.95$2.87$1.79$0.70RES $2.06SUP $0.79$1.852026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PCSA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PCSA Butterfly Map → + Track PCSA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +16.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PCSA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PCSA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PCSA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PCSA)

Health Care Rank #493 of 1015 ⚔️ SCNX vs PCSA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PCSA vs. SCNX, ADXN, LGVN, GELS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Processa Pharmaceuticals Inc. (PCSA) ranks #493 by composite RQD confidence (39/100, grade D-) and #935 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, PCSA leads on earnings valuation at N/A trailing P/E, while PCSA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with PCSA at 39/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PCSA ACTIVE
Processa Pharmaceuticals Inc.
D- 39/100 — — -35.0% -2.12% $5.3M Benchmark Subject
SCNX
Scienture Holdings Inc.
E 28/100 — 76.8% -35.0% +0.31% $5.3M /scnx-vs-pcsa →
ADXN
Addex Therapeutics Ltd
D 48/100 — — — -3.24% $5.3M /adxn-vs-pcsa →
LGVN
Longeveron Inc. (Class A)
E 27/100 — 67.0% -35.0% +2.40% $5.3M /lgvn-vs-pcsa →
GELS
Gelteq Limited
D+ 54/100 — — — -0.10% $5.2M /gels-vs-pcsa →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001533743 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Processa Pharmaceuticals Inc. (PCSA) reported GAAP revenue of $39.2M (+16.1% vs. FY2024 revenue of $33.7M , and +22.1% cumulative change since FY2023) , GAAP net income of -$13.6M, operating cash flow of -$11.4M, and free cash flow of -$11.4M (-1.2% YoY). On the balance sheet, PCSA closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $39.2M -$13.6M -$11.4M -$11.4M $7.8M —
FY2024 (FY) 2024-12-31 $33.7M -$11.8M -$11.2M -$11.2M $3.2M —
FY2023 (FY) 2023-12-31 $32.1M -$11.1M -$8.1M -$8.1M — —

3. PCSA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PCSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.85 (-2.12% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PCSA ranks #493 in composite RQD confidence.

How does PCSA compare to SCNX and ADXN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PCSA carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SCNX (Scienture Holdings Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and ADXN (Addex Therapeutics Ltd) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $5.3M). Among the 5-stock peer group, PCSA leads on earnings multiple (N/A) while PCSA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PCSA?

Per PCSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533743), Processa Pharmaceuticals Inc. generated $39.2M in revenue (+16.1% YoY), -$13.6M in net income, and -$11.4M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PCSA trading relative to its 50-day, 200-day, and 52-week technical levels?

PCSA last traded at $1.85 (-2.12% on volume of 36,621 shares), positioning the stock +0.54% above its 50-day simple moving average ($1.84) and -20.94% below its 200-day simple moving average ($2.34). Across its 52-week range of $1.04 to $10.25, PCSA sits at the 8.8% percentile with a 14-day RSI of 55.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.62 to $2.08).

Direct Sub-Reports: PCSA RQD Cockpit PCSA 12M Forecast PCSA Earnings & Move PCSA Dividends & DRIP PCSA Insiders & 13F PCSA Whale Options PCSA Profit Sankey PCSA News & Why
ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ SEC XBRL & RQD VERIFIED

PCSA — Processa Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Processa Pharmaceuticals Inc. (PCSA) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.85 (-2.12% 1D, market capitalization $5.3M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Processa Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations. The market capitalization is listed as $0.0B. Reported revenue was — in each of FY 2023, FY 2024, and FY 2025, indicating no reported revenue in the periods provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Processa Pharmaceuticals Inc. (PCSA) reported $39.2M in annual revenue (up from $33.7M in FY2024, +16.1% YoY) and -$13.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($32.1M revenue, -$11.1M net income) through FY2025, PCSA scaled operating cash flow to -$11.4M and free cash flow to -$11.4M, backed by $7.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 8/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $1.04 – $10.25 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

An investor should note that the pipeline (VT-7208) and the Vidya merger are the company's main external linkages per the news wire, but their supply-chain relationships are not mapped in the provided graph.

  • Key Question #1: Can PCSA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $39.2M and free cash flow of -$11.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PCSA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PCSA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Processa Pharmaceuticals Inc. (PCSA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PCSA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PCSA Bull vs. Bear Conversation Board — What's Your Call at $1.85?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PCSA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PCSA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $2.31 (+22.2%)
📌 Pinned Debate

A green-flagged FDA IND clearance for VT-7208 in urticaria, paired with a Generian partnership, offers a pipeline catalyst that could s

Picked up a starter position in PCSA in my $100K Virtual Cash book at $1.89. A green-flagged FDA IND clearance for VT-7208 in urticaria, paired with a Generian partnership, offers a pipeline catalyst that could support the stock independent of current financials.. Trading inside a $1.04–$10.25 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

RetailWhale_TX 🐂 BULL

Both sides have a point here — PCSA's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $1.63 (-13.8%)
Spot @ $1.89

Negative operating income in every reported period, a -35% ROIC, and a 2/9 Piotroski F-Score point to a cash-consuming balance sheet.

Fading this rally in PCSA at $1.89. Negative operating income in every reported period, a -35% ROIC, and a 2/9 Piotroski F-Score point to a cash-consuming balance sheet.. With a beta of 1.0 and the stock sitting at $1.89 (52-wk range $1.04–$10.25), the easy multiple expansion is already priced in.

LIVE TAPE